(2)
Lonza Signs Agreement to Divest Specialty Ingredients Business to Bain Capital and Cinven
Lonza Specialty Ingredients to be sold to Bain Capital and Cinven for an enterprise value of CHF 4.2 billion
Divestment will allow Lonza to refocus its business as a pure-play partner to the healthcare industry
Successful track record of investment in industrials sector and portfolio companies confirms that Bain Capital and Cinven are the right home for the business
Smooth transition for employees and customers is a priority for both seller and buyers. The transaction is anticipated to close in H2 2021
Quote from Albert Today s announcement is the result of a comprehensive and robust selection process.